At its April 1, 2020 meeting, the Board approved up to $50 million to fund a registry and randomized clinical trial of the effectiveness of hydroxychloroquine (HCQ) in preventing COVID-19 infections in US healthcare workers (HCWs). The trial will evaluate the use of HCQ in addition to usual practice to both prevent COVID-19 infection in exposed HCWs and limit the spread of the virus from infected HCWs who do not exhibit symptoms. Read more about the new study here.
All PCORI Board meetings are open to the public. This meeting was held via teleconference/webinar with no public comment period.